| Biotech Gossamer Bio. Inc. GOSS, +0.00% an immunology- and oncology-focused company with six drugs in its pipeline, priced its initial public offering of 17.25 million shares at $16 a share Thursday evening. The sale of the shares will raise about $276 million. Shares are expected to begin trading Friday morning on the Nasdaq under the ticker symbol "GOSS." Bank of America Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are the underwriters on the deal. Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here. Let's block ads! (Why?)
via Business - Latest - Google News https://on.mktw.net/2BrIRZP |  | If New feed item from http://ftr.fivefilters.org/makefulltextfeed.php?url=https%3A%2F%2Fnews.google.com%2Frss%2Ftopics%2FCAAqJggKIiBDQkFTRWd |  |
Unsubscribe from these notifications or sign in to manage your Email Applets.  |
0 Response to "Gossamer Bio prices IPO - MarketWatch"
Post a Comment